Evidence map›Paper›PMID 34889994›Full record

ArticleArchives of gynecology and obstetrics2022

Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer: a case-control study.

Kai Berner, Marc Hirschfeld, Daniela Weiß, Gerta Rücker, Jasmin Asberger, Andrea Ritter, Claudia Nöthling, Markus Jäger, Ingolf Juhasz-Böss, Thalia Erbes

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kai BernerDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.ORCID 0000-0002-7308-380X
Marc HirschfeldDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Daniela WeißDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Gerta RückerFaculty of Medicine, University of Freiburg, Freiburg, Germany.
Jasmin AsbergerDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Andrea RitterDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Claudia NöthlingDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Markus JägerDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Ingolf Juhasz-BössDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Thalia ErbesDepartment of Obstetrics and Gynecology, Medical Center, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. thalia.erbes@uniklinik-freiburg.de.
University of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOvarian cancer is the seventh most frequent form of malignant diseases in women worldwide and over 150,000 women die from it every year. More than 70 percent of all ovarian cancer patients are diagnosed at a late-stage disease with poor prognosis necessitating the development of sufficient screening biomarkers. MicroRNAs displayed promising potential as early diagnostics in various malignant diseases including ovarian cancer. The presented study aimed at identifying single microRNAs and microRNA combinations detecting ovarian cancer in vitro and in vivo.

methodsIntracellular, extracellular and urinary microRNA expression levels of twelve microRNAs (let-7a, let-7d, miR-10a, miR-15a, miR-15b, miR-19b, miR-20a, miR-21, miR-100, miR-125b, miR-155, miR-222) were quantified performing quantitative real-time-PCR. Therefore, the three ovarian cancer cell lines SK-OV-3, OAW-42, EFO-27 as well as urine samples of ovarian cancer patients and healthy controls were analyzed.

resultsMiR-15a, miR-20a and miR-222 showed expression level alterations extracellularly, whereas miR-125b did intracellularly across the analyzed cell lines. MicroRNA expression alterations in single cell lines suggest subtype specificity in both compartments. Hypoxia and acidosis showed scarce effects on single miRNA expression levels only. Furthermore, we were able to demonstrate the feasibility to clearly detect the 12 miRNAs in urine samples. In urine, miR-15a was upregulated whereas let-7a was down-regulated in ovarian cancer patients.

conclusionIntracellular, extracellular and urinary microRNA expression alterations emphasize their great potential as biomarkers in liquid biopsies. Especially, miR-15a and let-7a qualify for possible circulating biomarkers in liquid biopsies of ovarian cancer patients.

Indexed as

Circulating MicroRNAMicroRNAsOvarian NeoplasmsBiomarkersBiomarkers, TumorCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansBiomarkersBiomarkers, TumorCirculating MicroRNAMicroRNAsAcidosisDisease biomarkerHypoxiaLiquid biopsiesmicroRNAsOvarian cancerUrinary microRNAsUrine

Identifiers

PMID34889994
PMCPMC9300512
OpenAlexW4226310402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.